NEW YORK — Cosmetic drugmaker Allergan Inc. said Friday its eyelash treatment Latisse received Food and Drug Administration approval.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
The drug treats the condition hypotrichosis of the eyelashes and is applied once-daily to increase thickness and fullness, the company said. The treatment has full results within 16 weeks, it said.
"Latisse fulfills a significant and previously unmet need in the medical aesthetic marketplace with a product approved by the FDA that increases the growth of eyelashes, making them longer, thicker and darker," said Dr. Scott Whitcup, Allergan's executive vice president of research and development, in a statement.
The drug's active ingredient, bimatoprost, was first approved in 2001 as a treatment to lower intraocular pressure in people with a type of glaucoma or hypertension within the eye.
Allergan expects to launch Latisse in the first quarter and forecasts peak annual sales exceeding $500 million.
Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.